24 patents
Utility
Process for Preparing Enantiomerically Enriched Jak Inhibitors
12 Oct 23
Certain aspects of the present invention are directed to improved processes for preparing enantiomerically enriched intermediates for the synthesis of ruxolitinib and deuterated forms of ruxolitinib.
Sean Wiedemann, Cameron J. Cowden, Patrick Bazinet, Kathryn E. Kavouris, Kuo-Ming Wu, Robert S. Lewis
Filed: 12 Aug 21
Utility
Methods and Intermediates for Preparing Jak Inhibitors
14 Sep 23
Improved processes and intermediates for preparing ruxolitinib, deuterated analogs of ruxolitinib, and other JAK inhibitors are disclosed.
Patrick Bazinet, Robert S. Lewis, Mahender Karla, Yong Dong
Filed: 29 Jun 21
Utility
Combination of Morphinan Compounds and Antidepressant for the Treatment of Pseudobulbar Affect, Neurological Diseases, Intractable and Chronic Pain and Brain Injury
14 Sep 23
Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing.
Amanda Thomas
Filed: 6 Oct 22
Utility
Deuterated Analogs of D-serine and Uses Thereof
6 Oct 22
This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
Dario Doller, Christopher L. Brummel, Julie F. Liu, Roger D. Tung, Darren H. Wong, Tracey L. Petryshen, Raymond S. Hurst
Filed: 29 May 20
Utility
Process for Preparing Enantiomerically Enriched Jak Inhibitors
29 Sep 22
Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.
Robert S. Lewis, Mahender Reddy Karla, Kathryn E. Kavouris, Yong Dong, Adam J. Morgan, Cameron J. Cowden
Filed: 6 Feb 20
Utility
Methods of Treatment with Deuterated Analogs of D-serine
14 Jul 22
This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
Christopher L. Brummel
Filed: 29 May 20
Utility
Processes for the Preparation of Deuterated D-serine
2 Jun 22
Disclosed are methods for preparing deuterated analogs of D-serine and compounds useful for preparing deuterated analogs of D-serine.
Adam Morgan, Robert S. Lewis
Filed: 3 Apr 20
Utility
4-HYDROXYBUTYRIC Acid Analogs
26 May 22
This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing.
Roger D. Tung
Filed: 29 Oct 21
Utility
Combination of Morphinan Compounds and Antidepressant for the Treatment of Pseudobulbar Affect, Neurological Diseases, Intractable and Chronic Pain and Brain Injury
27 Jan 22
Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing.
Amanda Thomas
Filed: 22 Feb 21
Utility
4-HYDROXYBUTYRIC Acid Analogs
30 Dec 21
This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing.
Roger D. Tung, Adam J. Morgan
Filed: 1 Feb 21
Utility
Novel Deuterated Jak Inhibitor and Uses Thereof
16 Dec 21
I. Robert Silverman, Changhua Liu
Filed: 21 May 21
Utility
Morphinan Compounds
11 Nov 21
This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof.
Roger Tung
Filed: 14 Dec 20
Utility
Deuterated Derivatives of Ruxolitinib
28 Oct 21
I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
Filed: 10 Dec 20
Utility
Deuterated EPI-743
2 Sep 21
Julie F. Liu, Darren H. Wong
Filed: 18 Nov 16
Utility
Deuterated Analogs of D-beta-hydroxybutyric Acid and Uses Thereof
14 Jan 21
Roger D. Tung, I. Robert Silverman, Naeem Yusuff
Filed: 21 Sep 20
Utility
Deuterated Analogs of D-serine and Uses Thereof
16 Dec 20
This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
Dario Doller, Christopher L. Brummel, Julie F. Liu, Roger D. Tung
Filed: 26 May 20
Utility
4-HYDROXYBUTYRIC Acid Analogs
9 Dec 20
This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing.
Roger D. Tung
Filed: 9 Jan 20
Utility
Deuterated Analogs of D-serine and Uses Thereof
25 Nov 20
This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
Dario Doller, Christopher L. Brummel, Julie F. Liu, Roger D. Tung
Filed: 20 Nov 18
Utility
Treatment of Hair Loss Disorders with Deuterated Jak Inhibitors
15 Jul 20
Amanda T. Wagner, James V. Cassella, Philip B. Graham, Virginia Braman, Vinita Uttamsingh, Jana Von Hehn, Colleen E. Hamilton
Filed: 4 Dec 19
Utility
Morphinan Compounds
22 Jan 20
This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof.
Philip B. Graham, I. Robert Silverman
Filed: 25 Jul 19